Why the study?
Heart failure prevalence in type 2 diabetes mellitus remains high despite advances in glycemic control and cardiovascular risk management, suggesting non-hyperglycemic factors contribute to risk.
Does transcutaneous auricular vagus nerve stimulation (taVNS) improve cardiovascular outcomes and manage heart failure in patients with type 2 diabetes mellitus?
Does transcutaneous auricular vagus nerve stimulation (taVNS) improve cardiovascular outcomes and manage heart failure in patients with type 2 diabetes mellitus?
This review proposes transcutaneous auricular vagus nerve stimulation (taVNS) as a potential non-invasive therapy to address autonomic dysfunction and inflammation in the management of heart failure among patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
taVNS remains investigational for T2DM cardiovascular outcomes; leaves open efficacy pending randomized trials.
Patients with type 2 diabetes mellitus (T2DM) predominantly experience mortality due to cardiovascular diseases (CVD), particularly in low- and middle-income nations. Among these, heart failure (HF) is the most severe cardiovascular complication in terms of prognosis and management. Despite advancements in individualized glycemic control and cardiovascular risk management, including the development of novel glucose- and lipid-lowering agents, the prevalence of HF in T2DM patients remains persistently high. This indicates that factors beyond hyperglycemia significantly contribute to the heightened risk of HF associated with T2DM. This review examines critical factors influencing CVD risk in T2DM, particularly the roles of reduced heart rate variability (HRV), a marker of autonomic dysfunction, and chronic inflammation, both of which play pivotal roles in HF pathogenesis. Recent evidence highlights the potential of vagus nerve activation to modulate these risk factors, underscoring its capacity to reduce T2DM-related cardiovascular complications. Specifically, we discuss the therapeutic promise of transcutaneous auricular vagus nerve stimulation (taVNS) as a non-invasive intervention to enhance vagal tone, decrease systemic inflammation, and improve cardiovascular outcomes in T2DM. By addressing the interplay among HRV, microvascular disease, and inflammation, this review provides a comprehensive perspective on the potential utility of taVNS in managing HF in T2DM.
No takes yet. Share an insight, caveat, or question.
Thal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: